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Summary
Breast tumor infiltrating lymphocytes (TIL) are enriched in tumor-specific cytotoxic T lymphocytes (CTL), and
may represent a superior source of CTL compare to peripheral blood lymphocytes (PBL), for adoptive T cell
immunotherapy of breast cancer. However, the immunocompetence of TIL and the possibility to consistently
restore their tumor-specific lytic activity in vitro remains an open issue. In this study we evaluated the potential
of tumor antigen-pulsed fully mature dendritic cell (DC) stimulation in restoring tumor-specific cytotoxicity in
anergic TIL populations from advanced breast cancer patients. In addition we have compared tumor-specific T
cell responses induced by tumor antigen-loaded DC stimulation of TIL to responses induced from PBL. Although
TIL were consistently non-cytotoxic after isolation or culture in the presence of interleukin-2 (IL-2), in matched
experiments from three consecutive patients, tumor-lysate-pulsed DC-stimulated CD8+ T cell derived from TIL
were found to be significantly more cytotoxic than PBL (p < 0.05). In addition, cytotoxicity against autologous
tumor cells was more significantly inhibited by an anti-HLA class I (W6/32) MAb in TIL compared to PBL
(p < 0.05). CTL populations derived from TIL and PBL did not lyse autologous EBV-transformed lympho-
blastoid cell lines, and showed negligible cytotoxicity against the NK-sensitive cell line K562. Furthermore, in
both CD8+ T cell populations the majority of the tumor-specific CTL exhibited a Th1 cytokine bias (IFN-γhigh/
IL-4low). Taken together, these data show that tumor lysate-pulsed mature DC can consistently restore tumor-
specific lytic activity in non-cytotoxic breast cancer TIL. These results may have important implications for the
treatment of chemotherapy resistant breast cancer with active or adoptive immunotherapy.
Abbreviations: CTL: cytotoxic T lymphocyte; DC: dendritic cells; HLA: human leukocyte antigen; TIL: tumor
infiltrating lymphocytes; LCL: lymphoblastoid B-cell line
Introduction
Despite the use of cytoreductive surgery, and increas-
ingly intense chemotherapeutic and radiotherapeutic
regimens, early dissemination of treatment-resistant
tumor cells remains a major cause of metastatic recur-
rence and death in breast cancer patients [1, 2]. Several
reports have shown that most of the disseminated tu-
mor cells commonly detected in the bone marrow of
breast cancer patients rest in the G0 phase of the cell
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cycle [1, 3, 4]. Because of the poor prognostic im-
pact of detection of micrometastatic disease in breast
cancer patients [2] and the high resistance to chemo-
therapeutic agents in non-proliferating cells [3–5],
immunotherapy may represent an attractive treatment
option to offer to these patients.
Dendritic cells (DC) constitute a complex sys-
tem of professional antigen presenting cells (APC)
uniquely able to induce primary T and B cell responses
[6, 7]. Recently, the combination of GM-CSF and IL-4
has been shown to generate large numbers of myeloid
monocyte-derived DC [8–10]. However, these DC are
still immature. Although they may effectively capture
antigens, immature DC lack full T cell-stimulatory
activity and are sensitive to the immunosuppressive
effects of several immunoregulatory cytokines that can
be produced by tumors [7, 11]. In contrast, when
maturation is induced by appropriate stimuli, such as
monocyte-conditioned medium, LPS, or a cocktail of
inflammatory cytokines [7, 11, 12], DC demonstrate
a reduced ability to phagocytose antigens, but show a
significantly higher production of key cytokines (e.g.,
IL-12), increased resistance to the immunosuppres-
sive effects of IL-10, increased expression of T cell
adhesion and costimulatory molecules, and increased
expression of chemokine receptors that guide DC mi-
gration into lymphoid organs for priming of antigen-
specific T cells [7, 11]. It is thus apparent that the
maturation stage of DC is critical for their optimal use
in immunization strategies [13–15].
Tumor infiltrating lymphocytes (TIL) are present
in most human breast carcinomas and large numbers
of TIL have been found to express an activated pheno-
type implying that an immune response against cancer
cells is occurring in vivo [16–18]. Consistent with
this view, lymphocytes derived from tumor tissues of
breast cancer patients have been shown to be enriched
with tumor-specific cytotoxic T lymphocytes (CTL)
that can be stimulated to specifically kill breast can-
cer cells in vitro [16, 18–20]. However, TIL have
been shown to be defective in several immunologic
functions when compared to lymphocyte populations
derived from peripheral blood (PBL) [17, 21, 22].
Indeed, a poor ability to proliferate in the presence
of mitogens or low doses of IL-2, lack of cytotoxic
activity against autologous or allogenic tumor cells,
and alterations in the expression and/or function of
cytoplasmic CD3-ζ chain, which is essential for T cell
receptor (TcR) signaling, have been previously report-
ed in TIL recovered from breast and other cancers
[16–22]. Importantly, however, in some cases, poor
immune responses by explanted T lymphocytes could
be normalized upon in vitro culture with high doses
of recombinant IL-2 [23] or by T cell stimulation with
anti-CD3 and anti-CD28 [24]. It is therefore possible
that when stimulated by tumor-antigen-pulsed mature
DC, which are endowed with high expression of HLA
class I and II antigens and costimulatory molecules
[8–11], TIL may reverse their anergic state and be-
come a superior source of tumor specific CTL for
adoptive T cell immunotherapy of advanced or meta-
static breast cancer refractory to standard treatment
modalities.
In this study we have evaluated the potential of
fully mature tumor lysate-pulsed autologous DC in
restoring tumor-specific cytotoxicity in TIL from ad-
vanced breast cancer patients. Here we show for the
first time that autologous DC have the potential to
reverse the anergic state of TIL and that TIL consti-
tute a superior source of tumor-specific CD8+ CTL
compared to PBL.
Patients and methods
Tumor tissue, TIL and PBL were obtained from three
consecutive patients who had undergone total mastec-
tomy and lymphadenectomy for invasive breast can-
cer. Specimens were obtained at the time of surgery
through the Surgical Oncology Department and Patho-
logy Department at the University of Arkansas for
Medical Sciences (UAMS), Little Rock, AR, under
approval of the Institutional Review Board. Patients
1 and 2 were caucasian females with stage T4 N1
M0 and T2 N1 M0 ductal carcinoma and were age 35
and 54, respectively, while patient 3 was an African–
American female with stage T2 N1 M0 ductal ad-
enocarcinoma and was age 72. All three patients had
received no treatment prior to surgery.
Tumor cell lines
The natural killer (NK) sensitive target K562 (a hu-
man erythroleukemia cell line) was purchased from
American Type Culture Collection (ATCC) and was
maintained at 37◦C, 5% CO2 in complete media (CM)
containing RPMI 1640 (Invitrogen, Grand Island,
NY) and 10% fetal bovine serum (FBS, Gemini
Bioproducts, Calabasas, CA). Fresh breast tumor cells
were obtained from surgical specimens. Single cell
suspensions were obtained by processing solid tumor
samples under sterile conditions at room temperature
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as described [25, 26]. Briefly, viable tumor tissue was
mechanically minced in RPMI 1640 to portions no lar-
ger than 1–3 mm3 and washed twice with RPMI 1640.
The portions of minced tumor were then placed into
250 ml trypsinizing flasks containing 30 ml of enzyme
solution (0.14% collagenase Type I (Sigma, St. Louis,
MO) and 0.01% DNAse (Sigma, 2000 KU/mg)) in
RPMI 1640, and incubated on a magnetic stirring
apparatus overnight at 4◦C. Enzymatically dissoci-
ated tumor was then filtered through 150µm nylon
mesh to generate a single cell suspension. The resul-
tant cell suspension was then washed twice in RPMI
1640 plus 10% autologous plasma. Fresh tumor cell
lines were maintained in keratinocyte serum-free me-
dium (KSFM, Invitrogen), supplemented with 5 ng/ml
epidermal growth factor and 35–50µg/ml bovine pitu-
itary extract (Invitrogen) at 37◦C, 5% CO2. All exper-
iments were performed with fresh or cryopreserved
tumor cultures which had at least 90% viability and
contained >99% tumor cells.
Preparation of tumor lysate
(5–10)× 106 autologous tumor cells cultured in
KSFM were washed twice with phosphate-buffered
saline (PBS, pH 7.4) and harvested by scraping. Cells
were lysed by 3–4 freeze cycles (in liquid nitro-
gen) and thaw cycles (room temperature). Lysis was
monitored by light microscopy. Larger particles were
removed by centrifugation (10 min, 600 rpm), super-
natants were passed through a 0.2µm filter, and stored
at −80◦C until use.
Isolation of TIL from advanced breast
cancer patients
Single cell suspensions were obtained by processing
solid tumor samples as described above. The resultant
cell suspension containing tumor cells and TIL was
then washed twice in RPMI 1640 plus 10% autologous
plasma and placed on discontinuous Ficoll-Hypaque
(75/100%) density gradients and centrifuged again to
harvest TIL and tumor cells as previously described by
Whiteside et al. [27]. Enriched TIL preparations were
then washed twice in RPMI 1640 plus 10% autologous
plasma and either immediately stimulated with tumor
lysate-loaded DC (see below) or cryopreserved.
Isolation of PBL and generation of DC
PBL were separated from heparinized venous blood
by Ficoll-Hypaque (Sigma) density gradient centrifu-
gation and either cryopreserved in RPMI 1640 plus
10% DMSO and 25% autologous plasma, or im-
mediately used for DC generation. Briefly, PBMC
obtained from 42 ml of peripheral blood were placed
in six-well culture plates (Costar, Cambridge, MA)
in AIM-V (Invitrogen) at (0.5–1)× 107 per 3 ml per
well. After 2 h at 37◦C, non-adherent cells were re-
moved, and the adherent cells were cultured at 37◦C
in a humidified 5% CO2/95% air incubator, in AIM-
V medium supplemented with recombinant human
GM-CSF ((800 U/ml), Immunex, Seattle, WA) and
IL-4 ((1000 U/ml) R&D Systems, Minneapolis, MN).
Every 2 days, 1 ml of spent medium was replaced by
1.5 ml of fresh medium containing 1600 U/ml GM-
CSF and 1000 U/ml IL-4, to yield final concentrations
of 800 and 500 U/ml, respectively. After 6 days of
culture, final maturation of monocyte-derived DC was
induced by exposure during the last 48 h of culture
(i.e., day 6 to day 8) to TNF-α (1000 U/ml) IL-1β
(500 U/ml) (R&D Systems) and PGE2a (0.5µM/l)
(Sigma). After final maturation, DC were harvest-
ed for pulsing with breast tumor lysate as described
below.
DC pulsing
Following culture, fully mature DC were washed
twice in AIM-V and added to 50 ml polypropylene
tubes (Falcon, Oxnard, CA). The cationic lipid DO-
TAP (Boehringer Mannheim, Indianapolis, IN) was
used to deliver the total cell extract to DC. The 500µl
of total cell extract derived from 5×106 to 10×106 tu-
mor cells in AIM-V and DOTAP (125µg in 500µl of
AIM-V) were mixed in 12 mm × 75 mm polystyrene
tubes at room temperature for 20 min. The complex
was added to the DC in a total volume of 2–5 ml of
AIM-V and incubated at 37◦C in an incubator with oc-
casional agitation for 3 h. The cells were washed twice
with PBS and resuspended in AIM-V as described
below.
In vitro generation of tumor-specific CTL
Fresh or cryopreserved responder PBL and TIL were
washed and resuspended in AIM-V at (10–20)×
106 cells/well in six-well culture plates (Costar) with
tumor lysate-pulsed autologous DC (ratios from 20:1
to 30:1 responders PBL:DC). The cultures were
supplemented with recombinant human GM-CSF
(250 U/ml) and recombinant human IL-2 (10 U/ml
Aldesleukin, Chiron Therapeutics, Emeryville, CA)
and incubated at 37◦C. Control cultures consisted of
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matched autologous populations of CD8+ T cells
derived from PBL and TIL supplemented with cy-
tokines only (i.e., in the absence of DC) and cultured
in vitro for the same period of time. Human rIL-2
(10 U/ml) was added to the cultures every 3–4 days.
After 8–10 days PBL were restimulated once with
tumor lysate-loaded DC at a 20:1 ratio. At day 21,
CD8+ cells were separated from the bulk cultures by
positive selection with CD8-Dynabeads (Dynal Inc.,
Lake Success, NY) and further expanded in num-
ber for 10–14 days using autologous or allogeneic
irradiated PBL (5000 cGy) (1 × 106 cells/well) and
anti-CD3 monoclonal antibody (Ortho Pharmaceutical
Corp., Raritan, NJ) (0.2µg/ml) in AIM-V plus 5%
heat inactivated autologous plasma in 24-well plates
(Costar) before being assayed for CTL activity. In
some experiments, Dynabead-separated CD8+ T cells
were restimulate once more with autologous lethally
irradiated (10,000 cGy) tumor cells at a 20:1 lympho-
cyte/tumor ratios or tumor lysate pulsed DC before
being tested in cytotoxicity assay or being further
expanded with allogeneic irradiated PBL (5000 cGy)
(1×106 cells/well) and anti-CD3 monoclonal antibody
(as described above). As negative control targets, auto-
logous lymphoblasts were prepared by 3-day stim-
ulation with Con-A (1µg/ml, Invitrogen) in RPMI
1640 plus IL-2 (25 U/ml), while EBV-transformed
autologous lymphoblastoid B-cell lines (LCL) were
established by coculture of PBL with EBV-containing
supernatant from the B95.8 cell line in the presence of
1µg/ml cyclosporin A (Sandoz, Camberley, UK) and
were maintained in AIM-V supplemented with 10%
human AB serum (Gemini Bioproducts).
Cytotoxic activity
A standard 6 h chromium (51Cr) release assay was
performed to measure the cytotoxic reactivity of DC-
tumor lysate stimulated CD8+ T lymphocytes de-
rived from PBL and TIL. The K562 tumor cell line
was used as a target for the detection of NK activ-
ity. Con-A activated peripheral blood lymphocytes
and/or EBV-transformed LCL were used as autolo-
gous control targets. For determination of HLA class
I restriction of lysis, monoclonal antibodies (MAbs)
were used to block cytotoxicity. 51Cr-labeled tumor
targets were preincubated with MAbs specific for
monomorphic HLA class I W6/32 (50µg/ml) or iso-
type control (50µg/ml). The effector cells and 51Cr-
labeled targets were then incubated in a final volume
of 200µl/microwell at 37◦C with 6% CO2.
Phenotypic analysis of T cells
Flow cytometry was performed using fluorochrome-
conjugated MAbs directed against the following hu-
man leukocyte antigens: Leu-4 (CD3, pan T cells);
Leu-3 (CD4, T helper/inducer); Leu-2a (CD8, T cyto-
toxic/suppressor); Leu-19 (CD56, NK/K cells); Tac
(CD25, the IL-2R); anti-HLA-DR (L-243); anti TcR-
α/β or TcR-γ/δ (Becton Dickinson, San Jose, CA) and
analyzed on a FACScan (Becton Dickinson).
Flow cytometric analysis of intracellular
cytokines
Flow cytometric analysis of intracellular cytokine ex-
pression by stimulation with PMA and ionomycin was
conducted essentially as previously described [25, 26].
CD8+ T cells were tested after resting for 14 days
after the last antigen stimulation prior to activation by
PMA and ionomycin. Briefly, T cells (7.5 × 105/ml)
were incubated at 37◦C for 6 h in AIM-V plus 5%
autologous plasma and 50 ng/ml PMA and 500 ng/ml
ionomycin. The 10µg/ml Brefeldin A was added for
the final 3 h of incubation. Controls (non-activated
cultures) were incubated in the presence of Brefeldin
A only. The cells were harvested, washed and fixed
with 2% paraformaldehyde in PBS for 20 min at room
temperature, after which they were washed and stored
overnight in PBS at 4◦C. For intracellular staining,
the cells were washed and permeabilized by incuba-
tion in PBS plus 1% BSA and 0.5% saponin (S-7900,
Sigma) for 10 min at room temperature. Activated and
control cells were stained with FITC-anti-IFN-γ, and
PE-anti-IL-4, and isotype-matched controls (FITC-
anti-Igγ2a and PE-anti-Igγ1) from Becton-Dickinson.
After staining, cells were washed twice with PBS
plus 1% BSA and 0.5% saponin, once with PBS
plus 0.5% BSA, and fixed a second time with 2%
paraformaldehyde in PBS.
Results
Tumor-specific CD8+ cytotoxic responses
Cytotoxicity assays were conducted after a minimum
of 5 weeks after initiation of T lymphocyte cultures.
The results presented in Figure 1 represent the mean
of not less than three assays for each patient. CD8+
T cell cytotoxicity against autologous tumor cell tar-
gets was demonstrated for all three patients, ranging
from 22 to 38%, mean 30% (PBL) and from 39 to
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Figure 1. Tumor-specific CD8+ CTL responses induced in PBL and TIL by tumor lysate-pulsed DC in three patients with advanced breast
cancer, measured in a 6 h 51Cr-release assay. Percentage lysis (±standard deviation) at a 20:1 effector/target cell ratio is shown. Anti-HLA
class I blocking antibody (W6/32) and isotype control MAb (data not shown) were used at 50µg/ml. Patients 1–3; 1, autologous tumor; 2,
autologous tumor+W6/32 anti-class I MAb; 3, LCL control; 4, K562.
64%, mean 51% (TIL) (PT1), from 20 to 35%, mean
29% (PBL) and from 41 to 57%, mean 49% (TIL)
(PT2), and from 23 to 42%, mean 51% (PBL) and
from 58 to 80%, mean 69% (TIL) (PT3) at 20 effec-
tors per target. In contrast, pure populations of CD8+
T cells isolated from TIL cultured in low amounts
of IL-2 (i.e., not stimulated with DC) showed no
cytotoxicity against autologous tumor targets (data
not shown). DC-stimulated CD8+ T cell cytotoxicity
against the NK-sensitive cell line K562 was detectable
at a low level in all patients. The absence of signifi-
cant cytotoxicity against autologous EBV-transformed
LCL (Figure 1) demonstrated that, although these cells
were highly cytotoxic against autologous tumor cells,
they failed to kill autologous cells infected with EBV.
Blocking studies demonstrated in all cases that the
tumor-specific lytic activity against autologous tumor
targets was significantly inhibited by pre-treatment
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of tumor targets with MAb specific for HLA class I
(W6/32) (range of inhibition: from 16 to 52% (PBL)
and from 41 to 85% (TIL)) (Figure 1) (p < 0.05 by
Student’s t-test for all three patients) but not with
pre-treatment by isotype controls (data not shown).
Phenotypic analysis of lymphocytes
from peripheral blood and tumor tissue
Flow cytometric analysis was used to characterize the
phenotype of the populations of lymphocytes obtained
from PBL and TIL before and after the in vitro stimu-
lation with autologous tumor antigen-loaded DC. The
proportions of CD3+, CD8+ and CD4+ T cells in
PBL and TIL from the three breast cancer patients
evaluated in this study before DC activation are de-
scribed in Table 1. CD3+ T cells were the major
lymphocyte population in each tissue, with the per-
centage of CD4+ T cells greater than the percentage
of CD8+ T cells in PBL (p < 0.01) (Table 1). In con-
trast, in all three patients, TIL contained a similar
number of CD4+ and CD8+ T cells (Table 1). The
PBL had a CD4+ to CD8+ ratio of 2:1, while TIL
showed a ratio of 1:1 (Table 1). Starting lymphocyte
populations were also different in the percentage of
CD56 and CD19 positive lymphocytes, with PBL con-
taining more CD56+ and CD19+ cells compared to
TIL (p < 0.05 and p < 0.02 for CD56 and CD19,
respectively). The expression of CD56 on T lymph-
ocytes was further analyzed by two-color immuno-
fluorescence. By this technique, the CD8+ T cells
were compared for co-expression of CD56. PBL
Table 1. Subpopulations of mononuclear cells in PBL and TIL from
breast cancer patientsa
Specific MAb Percentage of Phenotype
Patient 1 Patient 2 Patient 3
PBL TIL PBL TIL PBL TIL
CD3 75 52 68 49 67 50
CD4 50 25 46 23 44 26
CD8 25 27 22 25 23 24
CD19 11 2 14 3 10 2
CD56 9 3 16 2 8 3
CD8/CD56 6 2 8 2 5 1
CD4/CD8 ratio 2.0 0.9 2.1 0.9 1.9 1.1
a Values are percentage of PBL and TIL that are positive for spe-
cific markers used in the cell staining before stimulation with tumor
lysate-pulsed autologous dendritic cells.
contained more CD8+/CD56+ T cells compared to
TIL (Table 1, p < 0.05).
After 21–28 days’ culture of autologous tumor
antigen-pulsed DC-stimulated PBL and TIL, the
striking majority of cells were found to be TcR-
αβ+/CD3+ T cells (90–97%). PBL contained more
CD4+ T cells (range from 58 to 89%) than CD8+ T
cells. In contrast, in the TIL populations derived from
all three patients, CD8+ T cells (range from 51 to
71%) were predominant over CD4+ T cells. Enriched
Figure 2. Two-color flow cytometric analysis of CD56 expres-
sion by breast tumor-specific CD8+ T cells in PBL and TIL
from a representative patient after in vitro stimulation with tumor
antigen-loaded DC.
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populations of CD8+ T cells were isolated at this time,
and analyzed for expression of CD56 after a further
two or more weeks of culture. A variable proportion of
CD8/CD56-antigen positive cells was detected in all
CD8+ T cells derived from PBL and TIL. However, as
representatively shown for patient 1 (Figure 2), auto-
logous tumor antigen-DC-stimulated TIL consistently
expressed a higher percentage of CD8+/CD56+ T
cells compared to PBL (p < 0.01). Further analysis
revealed the populations of CD8+ T cells from PBL
and TIL to be CD25+, HLA-DR+ and CD16− (data
not shown).
Two-color flow cytometric analysis
of intracellular IFN-γ and IL-4 expression
by tumor-specific T cells
To determine the pattern of Type 1 and Type 2 cytokine
expression in the populations of CD8+ T lymphocytes
collected from PBL and TIL, two-color flow cytomet-
ric analysis of intracellular IFN-γ or IL-4 expression
by CD8+ T cells was performed before and after in
vitro culture with DC-tumor lysate-loaded autologous
DC. As described in Table 2, at the beginning of
culture, significantly more CD8+ T cells from TIL
expressed IFN-γ than PBL-derived CD8+ T cells fol-
lowing PMA and ionomycin activation (p < 0.05). In
contrast, IL-4 expression was found at low, but signifi-
cantly higher levels in CD8+ T cells from PBL (p <
0.05) when compared to TIL (Table 2). When pure
populations of CD8+ T cells were tested after stimu-
lation with tumor lysate-loaded DC and further in vitro
expansion, significantly higher numbers of CD8+ T
cells from TIL were found to contain intracellular
IFN-γ compared to CD8+ T cells derived from PBL
(Table 2 and Figure 3) (p < 0.05). IL-4 expression
was again significantly higher in CD8+ T cells de-
Table 2. Percentage of IFN-γ and IL-4 positive CD8+ T cells
from PBL and TIL derived from breast cancer patientsa
Patient 1 Patient 2 Patient 3
IFN-γ IL-4 IFN-γ IL-4 IFN-γ IL-4
PBL 11 4 19 3 14 3
TIL 57 0.5 52 1 76 0.5
a Percentages of IFN-γ and IL-4 positive CD8+ T cells from
PBL and TIL before in vitro stimulation with tumor lysate-
pulsed autologous dendritic cells. The difference in IFN-γ
expression in PBL versus TIL before DC-stimulation was sig-
nificant at p > 0.05. The difference in IL-4 expression in PBL
versus TIL before DC-stimulation was significant at p > 0.05.
Figure 3. Representative dot plot analysis of intracellular IFN-γ
and IL-4 expression by CD8+ T cells from PBL and TIL for an
individual patient after in vitro culture with tumor antigen-loaded
DC. Lymphocytes were activated by PMA and ionomycin as de-
scribed in the Methods Section. Numbers in the quadrants represent
the percentage of CD8+ cytokine positive T lymphocytes.
rived from PBL when compared to IL-4 expression by
CD8+ T cells obtained from TIL with higher num-
bers of double positive (i.e., IFN-γ+/IL-4+) CD8+
T cells from PBL (Figure 3) (p < 0.05). Similar re-
sults were consistently obtained in several repetitive
analyses for all patients. Unactivated (i.e., resting)
CD8+ T cells failed to stain for IFN-γ or IL-4, and
similarly, FITC-anti-IgG2a and PE-anti-IgG1 isotype
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controls did not stain either activated or unactivated
CD8+ T cells (data not shown).
Discussion
DC play a crucial role during the priming and reac-
tivation of antigen-specific immune responses [6–10].
This unique function combined with the recent stan-
dardization of in vitro DC culture conditions may offer
the opportunity to test in large groups of cancer pa-
tients refractory to standard treatment modalities the
potential of DC-based immunotherapy. In this regard,
the use of mature versus immature DC may be critical
for their optimal use in immunization strategies [11–
15]. Indeed, recent clinical studies have shown that
monocyte-derived mature DC may rapidly generate
broad T cell immunity in healthy subjects vaccinated
with less than 3 × 106 antigen-pulsed autologous DC
[13, 14]. In contrast, the administration of immature
DC has been shown to result in inhibition of pre-
existing effector T cell function [15] with experiments
also providing direct evidence that antigen loaded im-
mature DC may silence T cells, either by peripheral
deletion, or expansion of regulatory T cells [28]. Sev-
eral human phase I/II trials have been initiated using
tumor antigen pulsed DC, and the induction of anti-
tumor immune responses and therapeutic benefit in the
absence of toxicity has been consistently observed in
at least a proportion of patients [29–34]. However, it
has become apparent that many late stage cancer pa-
tients may not be eligible for active immunization pro-
tocols because of either profound treatment-induced
immunosuppression or tumor-induced subversion of
the immune system [35–37]. Adoptive transfusions of
tumor-specific in vitro activated T cells, which avoid
the potential problems associated with inducing a CTL
response in vivo, might therefore be a more effec-
tive approach for control of tumor growth in patients
harboring advanced stage breast cancer.
Although the identity and distribution of antigenic
peptides and CTL epitopes presented by freshly iso-
lated breast tumors is still poorly known, recent studies
have unequivocally shown that multiple tumor anti-
gens do exist that can be recognized by CTLs and
used as target molecules to induce autologous tumor
cell killing in vitro [38–41]. In addition, several stud-
ies in breast and other cancers support the notion
that the accumulation of lymphocytes in tumor tissue
represents a specific immune response against tumor
cells [16–24]. In agreement with this view, T lympho-
cytes infiltrating human solid tumors represent an
enriched population of antigen-experienced CD8+ T
cells which have been previously demonstrated to be
endowed with 50–100 times stronger antitumor activ-
ity compare to in vitro activated PBL [42]. TIL could
therefore represent a superior source of tumor-specific
CTL to be used in adoptive immunotherapy for breast
cancer patients. Unfortunately, several reports have
shown that T cells derived from tumor tissue are
commonly defective in several immunologic functions
including a persistent lack of cytotoxicity when chal-
lenged against autologous or allogeneic tumor cells
[16–24]. The reason why TIL become anergic in vivo
is not well understood. However, tolerogenic imma-
ture DC endowed with low or absent costimulatory
activity and the ability to secrete high levels of im-
munosuppressive cytokines (i.e., IL-10 and TGF-β) as
well as the presence of regulatory T cells able to mit-
igate the immune response against breast cancer cells
have been recently identified in the peripheral blood
and tumor microenvironment of breast cancer patients
[36, 37, 43, 44].
In this study we have carefully analyzed the abil-
ity of fully mature DC to restore tumor-specific lytic
activity in TIL populations from advanced breast can-
cer patients. In addition, as a basis for the develop-
ment of more effective immunotherapy protocols for
the treatment of chemotherapy resistant disease, we
have performed a comparative phenotypic and func-
tional analysis of lymphocytes derived from PBL and
TIL before and after in vitro stimulation with tumor
antigen-pulsed autologous mature DC. We found TIL
to be a consistently superior source of tumor-specific
CTL compared to PBL. Indeed, although not cytotoxic
immediately after collection or when maintained in
low levels of IL-2 (data not shown), suggesting that a
state of anergy exists in vivo, induction of higher cyto-
toxic activity against autologous breast tumor cells
was consistently noted in TIL populations from all
three patients studied when compared to CD8+ T
cells derived from PBL. The lack of significant cyto-
toxicity against HLA-identical autologous LCL con-
firmed that, although TIL-derived CTL were highly
cytolytic against autologous tumor cells, they failed
to kill autologous control target cells expressing dif-
ferent antigens. Furthermore, the specificity of the
TIL-derived populations of CTL was also confirmed
by the significantly higher block in cytotoxic activity
detected using anti HLA class I MAb when com-
pared to PBL-derived CTL, and by their low cytotoxic
activity against K562 NK sensitive target cells.
Restoration of tumor-specific HLA class I restricted cytotoxicity 283
It is worth noting that while CD3+ T cells were the
major lymphocyte population detected in both tissues,
lymphocytes used at the time of in vitro stimulation
with tumor antigen-pulsed DC were predominantly
CD4+ T cells in PBL but not in TIL (CD4:CD8 ratio
2:1 v.s. 1:1, respectively). After in vitro restimula-
tion with antigen loaded fully mature DC, CD4+ T
cells remained predominant in PBL cultures, while in
TIL cultures a predominant population of CD8+ T
cells was consistently noted. CD56+/CD16+/CD3−
NK cells and CD8+/CD56+ T cells were predom-
inant in PBL compared to TIL at the beginning of
culture. However, after in vitro stimulation and expan-
sion of CD8+ T cells, TIL contained a significantly
higher percentage of CD8+/CD56+ T cells compared
to PBL. These results were found to correlate with
a significantly higher cytotoxic activity in the CD8+
CTL populations derived from TIL compared to those
derived from PBL. Taken all together these data sup-
port the view that, as previously described by us [25,
26] as well as others for CD8+ T cells derived from
peripheral blood [45], CD56 expression on CD8+ T
cells derived from TIL is an activation antigen asso-
ciated with higher cytotoxic function, rather than a
lineage-specific marker.
T cell-mediated protection from viral infection
as well as control of tumors is thought to be pro-
moted by Type 1 cytokine responses and impaired by
Type 2 cytokine responses [46]. Consistent with this
view, recent data have demonstrated that CD8+ T-cell
inhibition of tumor growth in vivo correlates more
with Type 1 cytokine production than with cytotoxic
function [47]. Recent studies, however, have shown
significant dysfunction of Type 1 T cell responses
in tumor bearing hosts [48, 49], suggesting that tu-
mor progression may be associated with a preferential
Type 2 T cell response. In this report, two-color flow
cytometric analysis of intracellular IFN-γ and IL-4 ex-
pression by tumor lysate-pulsed DC stimulated CD8+
T cells demonstrated that tumor-specific T cells from
advanced breast cancer patients showed even at this
advanced stage of the disease a large proportion of
Type 1 cytokine expressors in both the PBL and TIL
derived CD8+ CTL populations. Indeed, IL-4+ T
cells were detected in low numbers and mainly in
PBL. These data, therefore, suggest that this approach
is able, at least in vitro, to stimulate IFN-γ produc-
tion in CD8+ T cell populations derived from TIL
as well as to induce the differentiation from PBL of
Type 1 CD8+ T cells secreting IFN-γ and endowed
with cytotoxic activity against autologous tumor cells.
More importantly, these results suggest that the an-
ergy commonly seen in TIL population derived from
breast cancer patients [17, 21] may be reversible when
CD8+ T cells are removed from the tolerizing envi-
ronment and repetitively stimulated in vitro with fully
mature tumor antigen-pulsed-DC in the presence of
low amount of IL-2. Finally, these data suggest that
the lack of in vitro cytotoxic activity commonly detect-
ed in fresh TIL populations is not secondary to a Th2
cytokine switch.
In conclusion, although poor immune responses by
explanted T lymphocytes might be expected, it seems
possible to normalize in vivo defective immunologic
responses against breast tumors by in vitro T cell stim-
ulation with professional APC such as fully mature
DC. These results, combined with the evidence that
large numbers of late stage and heavily pretreated can-
cer patients are severely immunocompromised, and
that lymphocytes derived from TIL represent a su-
perior source of tumor-specific HLA class I-restricted
CTL compared to PBL, further support the use of
TIL in adoptive cellular immunotherapy of breast can-
cer patients harboring disease refractory to standard
treatment modalities. The future design and imple-
mentation of clinical trials will ultimately determine
the validity of this approach.
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